Chemopreventive and therapeutic efficacy of thymoquinone on experimentally induced hamster buccal pouch carcinogenesis

Aim: The present study aimed to investigate the chemopreventive and therapeutic effect of thymoquinone (TQ) on experimentally induced hamster buccal pouch carcinogenesis. Methodology :  40 Syrian male hamsters were classified into 4 equal groups (G(s)) of 10 each. GI: The animals remained untreated. The pouches of animals in GII, GIII, and GIV were painted 3 times a week for 14 weeks (ws). with 7,12-dimethylbenz (a) anthracene (DMBA). GII: No additional treatment was administered. Those in GIII: oral administration of TQ at a dose of 30 mg kg-1, one week before, as well as, during the application of DMBA on alternate days for 14 ws, whereas in GIV: The animals were injected intraperitoneally (IP) with TQ 50 mg/kg body weight thrice a week for 3ws. After the end of the experiment, the gross observations were made. Then, the fresh pouch specimens were surgically bisected into two pieces, one for Hematoxylin and Eosin (H&E) stain and immunohistochemistry (IHC) stain using Bcl-2. The other piece was used for apoptosis detection through a flow cytometry (FCM) test. Results: Gross observation showed variation in reduction of the tumor size in chemoprevention and treated group compared to the DMBA treated group.&nbsp

Therapeutic efficacy of time-dependent cetuximab on experimentally induced hamster buccal pouch carcinoma

Purpose: This study aimed to determine the cetuximab therapeutic potential in the time-dependent fashion in experimentally induced hamster buccal pouch (HBP) carcinoma. Material and methods:  Forty Syrian male hamsters were classified into four equal groups (G) of ten each. GI: The animals remained untreated to act as negative controls. The right pouches of animals in GII, GIII, and GIV were painted three times a week for 14 weeks (w)s with 7,12-dimethylbenz (a) anthracene (DMBA). GII: No additional treatment was administered. While, the animals in GIII and GIV were treated differently. Those in GIII received cetuximab intraperitoneally (IP) three intervals a week for three (w)s, whereas those in GIV received cetuximab IP three intervals for six (w)s. After the end of the experiment, the gross observations were made, and blood samples (2ml) were withdrawn from the inner canthus of the eye for analysis of whole white blood cells (WBCs) and oxidative stress markers [glutathione (GSH) and malondialdehyde (MDA) levels].  All pouches were surgically bisected for preparation for Hematoxylin and Eosin (H&E) stain and immunohistochemistry (IHC) stain using epidermal growth factor receptor (EGFR). Other fresh tissue was used for DNA detection through a flow cytometry (FCM) test

Bendamustine Associated with Irreversible Ascending Paralysis

Bendamustine is an alkylating agent currently used in the treatment of lymphoproliferative disorders. Many adverse effects, including a rare case of reversible neurotoxicity, have been reported in association with bendamustine. Herein, we report the first case of irreversible ascending paralysis related to bendamustine